248 related articles for article (PubMed ID: 22048979)
1. Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy.
Gerritsen WR; Sharma P
J Clin Immunol; 2012 Feb; 32(1):25-35. PubMed ID: 22048979
[TBL] [Abstract][Full Text] [Related]
2. A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
Heidegger I; Necchi A; Pircher A; Tsaur I; Marra G; Kasivisvanathan V; Kretschmer A; Mathieu R; Ceci F; van den Bergh RCN; Thibault C; Tilki D; Valerio M; Surcel C; Gandaglia G;
Eur Urol Oncol; 2021 Oct; 4(5):745-754. PubMed ID: 33243663
[TBL] [Abstract][Full Text] [Related]
3. Management of patients with castration-resistant disease.
Pezaro C; Omlin A; Lorente D; de Bono J
Hematol Oncol Clin North Am; 2013 Dec; 27(6):1243-60, ix. PubMed ID: 24188261
[TBL] [Abstract][Full Text] [Related]
4. The evolving role of immunotherapy in prostate cancer.
Cordes LM; Gulley JL; Madan RA
Curr Opin Oncol; 2016 May; 28(3):232-40. PubMed ID: 26977847
[TBL] [Abstract][Full Text] [Related]
5. Advances in immunotherapy of castration-resistant prostate cancer: bisphosphonates, phosphoantigens and more.
Dieli F; Caccamo N; Meraviglia S
Curr Opin Investig Drugs; 2008 Oct; 9(10):1089-94. PubMed ID: 18821471
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
Laccetti AL; Subudhi SK
Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
[TBL] [Abstract][Full Text] [Related]
7. New therapies for castration-resistant prostate cancer: efficacy and safety.
Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
[TBL] [Abstract][Full Text] [Related]
8. Novel options for the treatment of castration-resistant prostate cancer.
Ohlmann CH; Merseburger AS; Suttmann H; Schilling D; Trojan L; Kempkensteffen C; Corvin S; Mathers MJ; Bastian PJ
World J Urol; 2012 Aug; 30(4):495-503. PubMed ID: 22101903
[TBL] [Abstract][Full Text] [Related]
9. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
[TBL] [Abstract][Full Text] [Related]
10. [Immunotherapy: an emerging strategies against prostate castration resistant cancer].
Mansi L; Thiery-Vuillemin A; Kalbacher E; Nguyen T; Maurina T; Nallet J; Kim S; Borg C; Kleinclauss F; Pivot X; Adotevi O
Bull Cancer; 2012 Jul; 99 Suppl 1():S57-65. PubMed ID: 22516539
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization.
Reimers MA; Slane KE; Pachynski RK
Curr Urol Rep; 2019 Sep; 20(10):64. PubMed ID: 31482315
[TBL] [Abstract][Full Text] [Related]
12. Novel therapies for the treatment of advanced prostate cancer.
Clarke JM; Armstrong AJ
Curr Treat Options Oncol; 2013 Mar; 14(1):109-26. PubMed ID: 23322116
[TBL] [Abstract][Full Text] [Related]
13. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
14. Novel chemotherapies in development for management of castration-resistant prostate cancer.
Tewari AK; George DJ
Curr Opin Urol; 2013 May; 23(3):220-9. PubMed ID: 23511791
[TBL] [Abstract][Full Text] [Related]
15. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic compounds in the treatment of castration-resistant prostate cancer.
Lee P; Aragon-Ching JB
Anticancer Agents Med Chem; 2009 Dec; 9(10):1040-5. PubMed ID: 19719458
[TBL] [Abstract][Full Text] [Related]
17. Castration-resistant prostate cancer: targeted therapies.
Leo S; Accettura C; Lorusso V
Chemotherapy; 2011; 57(2):115-27. PubMed ID: 21430379
[TBL] [Abstract][Full Text] [Related]
18. New therapies for castrate-resistant prostate cancer.
Williams SB; Lay AH; Lau CS; Josephson DY; Wilson TG; Choueiri TK; Pal SK
Expert Opin Pharmacother; 2011 Sep; 12(13):2069-74. PubMed ID: 21663529
[TBL] [Abstract][Full Text] [Related]
19. Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review.
Kim TJ; Koo KC
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751945
[TBL] [Abstract][Full Text] [Related]
20. Novel approaches and future directions in castration-resistant prostate cancer.
Nabhan C; Parsons B; Touloukian EZ; Stadler WM
Ann Oncol; 2011 Sep; 22(9):1948-1957. PubMed ID: 21252057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
